A truth serum for cancer — microRNAs have major potential as cancer biomarkers

Chin, Lena J.; Slack, Frank J.

doi:10.1038/cr.2008.290

Cited by 88 publications

(61 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15,31 In this study, we demonstrated a distinct plasma miRNA expression pattern in hypertensive patients, including 9 miRNAs that were upregulated and 18 miRNAs that were downregulated compared with healthy control subjects. Surprisingly, we found that an HCMV-encoded miRNA, hcmv-miR-UL112, was highly expressed in hypertensive patients.…”

Section: Discussionmentioning

confidence: 63%

“…13,14 miRNAs are stable in plasma and serum and may be suitable as blood-based biomarkers in different cancers and other diseases. 15,16 In this study, we demonstrate the expression pattern of miRNAs in the plasma of patients with essential hypertension. We found hcmv-miR-UL112, a human cytomegalovirus (HCMV)-encoded miRNA, is highly expressed in hypertensive patients compared with control subjects.…”

mentioning

confidence: 63%

See 1 more Smart Citation

Signature microRNA Expression Profile of Essential Hypertension and Its Novel Link to Human Cytomegalovirus Infection

et al. 2011

View full text Add to dashboard Cite

Background-Essential hypertension has been recognized as a disease resulting from a combination of environmental and genetic factors. Recent studies demonstrated that microRNAs (miRNAs) are involved in cardiac hypertrophy and heart failure. However, little is known about the roles of miRNAs in essential hypertension. Methods and Results-Using microarray-based miRNA expression profiling, we compared the miRNA expressions in plasma samples from 13 hypertensive patients and 5 healthy control subjects. Twenty-seven miRNAs were found to be differentially expressed. The expressions of selected miRNAs (miR-296 -5p, let-7e, and a human cytomegalovirus [HCMV]-encoded miRNA, hcmv-miR-UL112) were validated independently in plasma samples from 24 hypertensive patients and 22 control subjects. The absolute expression levels of hcmv-miR-UL112, miR-296 -5p, and let-7e were further determined in 127 patients and 67 control subjects (fold changes are 2.5, 0.5, and 1.7 respectively; all PϽ0.0001). Additionally, we demonstrated that interferon regulatory factor 1 is a direct target of hcmv-miR-UL112.Increased HCMV seropositivity and quantitative titers were found in the hypertension group compared with the control group (52.7% versus 30.9%, Pϭ0.0005; 1870 versus 54 copies per 1 mL plasma, PϽ0.0001). Seropositivity, log-transformed copies of HCMV, and hcmv-miR-UL112 were independently associated with an increased risk of hypertension (odds ratio, 2.48; 95% confidence interval, 1.48 to 4.15; Pϭ0.0005; odds ratio, 1.97; 95% confidence interval, 1.58 to 2.46; PϽ0.0001; and odds ratio, 2.55; 95% confidence interval, 1.98 to 3.27; PϽ0.0001, respectively). Conclusions-We report for the first time a circulating miRNA profile for hypertensive patients and demonstrate a novel link between HCMV infection and essential hypertension. These findings may reveal important insights into the pathogenesis of essential hypertension. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00420784. Key Words: cytomegalovirus Ⅲ hypertension Ⅲ interferon regulatory factor-1 Ⅲ microRNAs E ssential hypertension is a predisposing risk factor for stroke, myocardial infarction, congestive heart failure, and arterial aneurysm; it is also the leading cause of chronic renal failure. 1 Approximately 90% to 95% of hypertension, affecting Ͼ1 billion adults worldwide, is the essential hypertension subtype. 2 Discernment between essential and secondary hypertension is critical because the former has no precise cause and the latter has a clear cause usually remediable by a Clinical Perspective on p 184 microRNAs (miRNAs) are short, endogenous, noncoding RNAs that regulate gene expression at the posttranscriptional level by binding to the 3Ј untranslated regions (UTRs) of their target mRNAs. 7 Although dysregulation of miRNA expression is a feature of malignancies, 8 -10 research into miRNAs in biological processes reveals their regulation of immune cell development, 11 involvement in inflammatory response, 12 and critical participation...

show abstract

Section: Discussionmentioning

confidence: 63%

mentioning

confidence: 63%

Signature microRNA Expression Profile of Essential Hypertension and Its Novel Link to Human Cytomegalovirus Infection

et al. 2011

View full text Add to dashboard Cite

show abstract

“…It was demonstrated that the expression levels of miR-21, miR-92, miR-93, miR-126 and miR-29a in the serum of ovarian cancer patients were significantly upregulated, whereas those of miR-155, miR-127 and miR-99b were significantly reduced (5,6). In patients with diffuse large B-cell lymphoma, the serum miR-21 expression level was significantly increased, and the upregulation of miR-21 expression was also correlated with a higher recurrence-free survival rate (7,8). These results suggest that the detection of the specific expression of miRNAs not only assists in the early diagnosis of cancer, but also in the determination of the patient's prognosis.…”

Section: Introductionmentioning

confidence: 83%

Serum miRNA expression in patients with esophageal squamous cell carcinoma

et al. 2015

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the feasibility and value of serum microRNAs (miRNAs/miRs) as biological markers for the prediction of the behavior and prognosis of esophageal squamous cell cancer (ESCC). The differential expression of serum miRNA was detected by an miRNA microarray of 9 patients with ESCC and 9 healthy volunteers. The result of the miRNA microarray was validated in serum samples of 69 patients with ESCC and 14 healthy volunteers by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The association between serum miRNA expression and tumor-node-metastasis (TNM) stage was analyzed. A total of 10 serum-specific miRNAs were identified from the patients with ESCC. Through PCR verification, the expression levels of miR-129, miR-451 and miR-365 were consistent with the microarray results validated by RT-qPCR, and the difference was statistically significant compared with the healthy volunteers (P=0.007, P=0.007 and P<0.001, respectively). Multivariate logistic regression analysis showed that miR-365 could serve as potential diagnostic marker for ESCC; the area under the receiver operating characteristic curve was 0.831, with a sensitivity of 80.56% and a specificity of 86.7%, but its expression did not differ significantly among the different TNM stages (stage I-II vs. III, P=0.052; stage III vs. IV, P= 0.069). The expression level of miRNA-129 differed significantly among the different stages (stage I-II vs. III, , P=0.002; stage III vs. IV, P=0.042), while the expression level of miR-451 did not differ significantly between stage III and IV (P=0.308). In conclusion, serum microRNAs are novel biomarkers for ESCC, and miRNA-365 and miRNA-129 can be used for the early prediction of cancer and the prediction of clinical stage, respectively.

show abstract

“…Ke ztrátě funkce miRNA dochází několika způsoby -mutace genu pro miRNA, miRNA posttranskripční úprava a epigenetické změny. Vzhledem k tomu, že miRNA se podílí na řízení buněčného cyklu, metabolizmu a vývoji buňky, tak změna exprese (up-či down-regulace exprese miRNA) bude mít za následek proto-onkogenní (progrese a růst nádoru) či tumor supresivní (inhibice růstu a proliferace) dů-sledky pro buňky [51,52,55,56], jelikož miRNA, která je nadmíru exprimována v nádorových buňkách, pravděpodobně funguje jako inhibitor tumor supresivních genů. Na druhou stranu miRNA, která má sníženou expresi v nádorových buňkách, může zapříčinit snížení exprese onkogenů v normální tkáni.…”

Section: Obr 2 Kras Signální Dráhaunclassified

“…Role miRNA je dána typem tkáně a charakterem genu, který reguluje. MiRNA je krátká nekódující RNA o délce 22-23 nukleotidů, která je kódo-vána v DNA [51,52]. MiRNA je kódována strukturálními geny (70 %), ale také intergenovou nekódující DNA (30 %), která není vázána na expresi genů jako takových.…”

Section: Mikrorna a Crcunclassified

Molecular Pathogenesis of Colorectal Cancer

Král¹,

Slyšková²,

Vodička³

et al. 2016

Klin Onkol

View full text Add to dashboard Cite

2 Oddělení molekulární biologie nádorů, Ústav experimentální medicíny, AV ČR, v.v.i., Praha SouhrnVýchodiska: Kolorektální karcinom (colorectal cancer -CRC) je nádorové onemocnění tlustého střeva s každoročně dia gnostikovanými téměř 1,3 miliony nových pa cientů celosvětově. Mortalita na toto závažné nádorové onemocnění dosahuje již 8,5 %. Jedná se o 2. nečastější nádo-rové onemocnění u žen (1. nádor prsu) a 3. u mužů (1. nádor plic, 2. nádor prostaty). Tímto CRC patří vedle nádorů prsu, prostaty a plic k nejčastějším nádorovým onemocnění u mužů a žen na světě. V České republice je stále více než 50 % pa cientů s CRC dia gnostikováno v pokroči-lém stadiu (stadium III a IV). Z molekulárně genetického pohledu je CRC velice heterogenní onemocnění, na kterém se podílí mnoho faktorů. CRC má formu jak hereditární, kde dominují mutace v genech APC (FAP, aFAP), MMR (HNPCC) atd., jejíž výskyt se pohybuje okolo 5-10 %, tak formu sporadickou s výskytem 90-95 %, kde dochází k postupné akumulaci mutací v široké škále genů. Znalost genetické podstaty (APC, KRAS, MMR, mikroRNA, CIMP atd.) jak hereditární, tak sporadické formy CRC je nezbytná nejen pro zahájení léčby, ale také pro odhadnutí celkového rizika, prognózy a následného follow-up pa cienta. Závěr: Tento článek shrnuje dosavadní molekulárně genetické aspekty patogeneze CRC. Klíčová slovakolorektální karcinom -patogeneze -hereditární -sporadický -rizikové faktory SummaryBackground: Colorectal cancer (CRC) remains a major health burden with an incidence of 1.3 million new cases worldwide and a mortality of almost 8.5%. It is the 2 nd most common cancer in women (1 st breast carcinoma) and 3 rd most common in men (1 st lung carcinoma, 2 nd prostate carcinoma). CRC alongside breast, lung, prostate and stomach cancer is in the top five most common cancers in men and women worldwide. There are still more than 50% of CRC patients diagnosed with advanced disease (stage III and IV) in the Czech Republic. Genetically, CRC is a very heterogeneous disease with many factors playing key roles in pathogenesis. There are two types of CRC, hereditary with an incidence of between 5% and 10% with APC (FAP, aFAP) or MMR (HNPCC) genes affected, and sporadic colorectal cancer with an incidence of 90-95% with a lot of mutations in variable genes that accumulate during pathogenesis (APC, KRAS, MMR, microRNA, CIMP etc.). Knowledge of the molecular pathogenesis of CRC (hereditary, sporadic) is crucial for treatment, assessment of risk, prognosis, and patient follow-up. Conclusion: This article summarizes the molecular pathogenesis of sporadic and hereditary CRC.

show abstract

A truth serum for cancer — microRNAs have major potential as cancer biomarkers

Cited by 88 publications

References 9 publications

Signature microRNA Expression Profile of Essential Hypertension and Its Novel Link to Human Cytomegalovirus Infection

Signature microRNA Expression Profile of Essential Hypertension and Its Novel Link to Human Cytomegalovirus Infection

Serum miRNA expression in patients with esophageal squamous cell carcinoma

Molecular Pathogenesis of Colorectal Cancer

Contact Info

Product

Resources

About